Chicago Partners Investment Group LLC Buys 4,230 Shares of Merck & Company, Inc. (MRK)

Chicago Partners Investment Group LLC increased its stake in shares of Merck & Company, Inc. (NYSE:MRK) by 2,104.5% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 4,431 shares of the company’s stock after buying an additional 4,230 shares during the period. Chicago Partners Investment Group LLC’s holdings in Merck & Company were worth $277,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of MRK. Vanguard Group Inc. boosted its position in shares of Merck & Company by 1.9% in the second quarter. Vanguard Group Inc. now owns 174,819,694 shares of the company’s stock valued at $10,071,362,000 after buying an additional 3,242,254 shares during the period. BlackRock Institutional Trust Company N.A. boosted its position in shares of Merck & Company by 0.7% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 74,363,785 shares of the company’s stock valued at $4,284,098,000 after buying an additional 535,407 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Merck & Company by 2.2% in the third quarter. Bank of New York Mellon Corp now owns 56,714,385 shares of the company’s stock valued at $3,539,544,000 after buying an additional 1,235,395 shares during the period. BlackRock Fund Advisors boosted its position in shares of Merck & Company by 4.0% in the second quarter. BlackRock Fund Advisors now owns 44,732,600 shares of the company’s stock valued at $2,577,045,000 after buying an additional 1,701,520 shares during the period. Finally, Northern Trust Corp boosted its position in shares of Merck & Company by 1.1% in the third quarter. Northern Trust Corp now owns 36,237,082 shares of the company’s stock valued at $2,261,555,000 after buying an additional 411,890 shares during the period. Hedge funds and other institutional investors own 73.80% of the company’s stock.

Institutional Ownership by Quarter for Merck & Company (NYSE:MRK)

Shares of Merck & Company, Inc. (NYSE:MRK) traded down 0.37% during mid-day trading on Friday, reaching $64.15. 8,531,370 shares of the company were exchanged. The firm’s 50-day moving average is $61.60 and its 200-day moving average is $61.72. The company has a market capitalization of $176.87 billion, a price-to-earnings ratio of 31.45 and a beta of 0.79. Merck & Company, Inc. has a 12 month low of $49.24 and a 12 month high of $65.46.

Merck & Company (NYSE:MRK) last released its earnings results on Thursday, February 2nd. The company reported $0.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.89 by $0.00. Merck & Company had a net margin of 14.30% and a return on equity of 24.08%. The company earned $10.10 billion during the quarter, compared to the consensus estimate of $10.22 billion. During the same quarter in the prior year, the firm earned $0.93 EPS. The company’s revenue was down 1.0% compared to the same quarter last year. On average, equities analysts forecast that Merck & Company, Inc. will post $3.81 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was first reported by sleekmoney and is the sole property of of sleekmoney. If you are reading this news story on another publication, it was illegally copied and reposted in violation of US and international copyright and trademark legislation. The original version of this news story can be read at http://sleekmoney.com/chicago-partners-investment-group-llc-buys-4230-shares-of-merck-company-inc-mrk/1656127.html.

MRK has been the topic of a number of analyst reports. Zacks Investment Research raised Merck & Company from a “hold” rating to a “buy” rating and set a $70.00 price objective on the stock in a report on Friday, October 14th. Vetr lowered Merck & Company from a “sell” rating to a “strong sell” rating and set a $52.27 price objective on the stock. in a report on Tuesday, December 27th. Bryan, Garnier & Co initiated coverage on Merck & Company in a report on Friday, January 13th. They issued a “buy” rating on the stock. Jefferies Group LLC lowered Merck & Company from a “hold” rating to an “underperform” rating and set a $48.00 price objective on the stock. in a report on Monday, December 19th. Finally, J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Merck & Company in a report on Wednesday, January 11th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and thirteen have given a buy rating to the company’s stock. Merck & Company currently has an average rating of “Buy” and a consensus target price of $66.91.

In other Merck & Company news, EVP Michael J. Holston sold 91,959 shares of the stock in a transaction that occurred on Friday, February 3rd. The shares were sold at an average price of $63.96, for a total value of $5,881,697.64. Following the completion of the sale, the executive vice president now owns 105,559 shares in the company, valued at approximately $6,751,553.64. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Patricia F. Russo sold 5,000 shares of the stock in a transaction that occurred on Wednesday, February 8th. The stock was sold at an average price of $64.42, for a total transaction of $322,100.00. Following the completion of the sale, the director now owns 18,148 shares of the company’s stock, valued at approximately $1,169,094.16. The disclosure for this sale can be found here. In the last quarter, insiders sold 106,959 shares of company stock valued at $6,843,448. Insiders own 0.05% of the company’s stock.

Merck & Company Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

5 Day Chart for NYSE:MRK

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/chicago-partners-investment-group-llc-buys-4230-shares-of-merck-company-inc-mrk/1656127.html

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *